Bortezomib

Identification

Are you a

new drug developer?

Contact us to learn more about our customized products and solutions.

Name

Bortezomib

Accession Number

DB00188  (APRD00828, DB07475)

Type

Small Molecule

Groups

Approved, Investigational

Description

Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells.

Bortezomib is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Bortezomib (DB00188)

×

Close

Synonyms

• [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
• Bortezomib
• N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide

External IDs

BXCL 101 / BXCL-101 / BXCL101 / LDP 341 / LDP-341 / LDP341 / PS 341 / PS-341 / PS341

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Act Bortezomib	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Actavis Pharma Company	2015-11-17	Not applicable
Bortezomib	Injection, powder, lyophilized, for solution	1 mg/1mL	Intravenous	Fresenius Kabi	2017-11-06	Not applicable
Bortezomib	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Apotex Corporation	Not applicable	Not applicable
Bortezomib for Injection	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Sandoz Canada Incorporated	Not applicable	Not applicable
Bortezomib for Injection	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Pfizer	Not applicable	Not applicable
Bortezomib for Injection	Powder, for solution	2.5 mg	Intravenous; Subcutaneous	Pfizer	Not applicable	Not applicable
Bortezomib for Injection	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Teva	2015-01-06	Not applicable
Bortezomib for Injection	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Dr Reddy's Laboratories	2017-03-21	Not applicable
Velcade	Injection, powder, for solution	1.0 mg	Intravenous	Janssen Cilag International Nv	2004-04-26	Not applicable
Velcade	Injection, powder, for solution	3.5 mg	Intravenous; Subcutaneous	Janssen Cilag International Nv	2004-04-26	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bortezomib Accord	Injection, powder, for solution	3.5 mg	Intravenous; Subcutaneous	Accord Healthcare Limited	2015-07-20	Not applicable
Bortezomib Hospira	Injection, powder, for solution	3.5 mg	Intravenous; Subcutaneous	Hospira, Inc.	2016-07-22	Not applicable
Bortezomib Sun	Injection, powder, for solution	3.5 mg	Intravenous; Subcutaneous	Sun Pharmaceutical Industries (Europe) B.V.	2016-07-22	Not applicable
PMS-bortezomib	Powder, for solution	3.5 mg	Intravenous; Subcutaneous	Pharmascience Inc	Not applicable	Not applicable

Categories

• Acids
• Acids, Noncarboxylic
• Antineoplastic Agents
• Antineoplastic and Immunomodulating Agents
• Boron Compounds
• Boronic Acids
• Cardiotoxic antineoplastic agents
• Cytochrome P-450 CYP1A2 Inhibitors
• Cytochrome P-450 CYP1A2 Inhibitors (moderate)
• Cytochrome P-450 CYP1A2 Inhibitors (weak)
• Cytochrome P-450 CYP1A2 Substrates
• Cytochrome P-450 CYP2C19 Inhibitors
• Cytochrome P-450 CYP2C19 Inhibitors (weak)
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2C9 Substrates
• Cytochrome P-450 CYP2D6 Substrates
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (weak)
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 Enzyme Inhibitors
• Hypotensive Agents
• Immunosuppressive Agents
• Myelosuppressive Agents
• Potential QTc-Prolonging Agents
• Proteasome Inhibitors
• Pyrazines
• QTc Prolonging Agents

UNII

69G8BD63PP

CAS number

179324-69-7

Weight

Average: 384.237
Monoisotopic: 384.196885774

Chemical Formula

C₁₉H₂₅BN₄O₄

InChI Key

GXJABQQUPOEUTA-RDJZCZTQSA-N

InChI

InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

IUPAC Name

[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid

SMILES

CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O

Pharmacology

Indication

For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.

Associated Conditions

• Mantle Cell Lymphoma (MCL)
• Multiple Myeloma (MM)

Pharmacodynamics

Bortezomib is a drug that inhibits the mammalian 26S proteasome. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma. Tumor cells, that is, rapidly dividing cells, appear to be more sensitive to proteasome inhibition.

Mechanism of action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. In addition, bortezomib appears to increase the sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).

Target	Actions	Organism
AProteasome subunit beta type-5	inhibitor	Humans
AProteasome subunit beta type-1	inhibitor	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

83% over the concentration range of 100-1000 ng/ml.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolized via cytochrome P450 enzymes 3A4, 2C19, and 1A2, while bortezomib metabolism by CYP 2D6 and 2C9 enzymes is minor. The major metabolic pathway is deboronation to form 2 deboronated metabolites that subsequently undergo hydroxylation to several metabolites which are inactive as 26S proteasome inhibitors.

• Bortezomib
  Bortezomib metabolite M1
  • Bortezomib metabolite M1
    Bortezomib metabolite M3
    • Bortezomib metabolite M3
      Bortezomib metabolite M4
  • Bortezomib metabolite M1
    Bortezomib metabolite M5
  • Bortezomib metabolite M1
    Bortezomib metabolite M25
  • Bortezomib metabolite M1
    Bortezomib metabolite M26
• Bortezomib
  Bortezomib metabolite M2
  • Bortezomib metabolite M2
    Bortezomib metabolite M3
  • Bortezomib metabolite M2
    Bortezomib metabolite M6
  • Bortezomib metabolite M2
    Bortezomib metabolite M8
    • Bortezomib metabolite M8
      Bortezomib metabolite M33
  • Bortezomib metabolite M2
    Bortezomib metabolite M27
  • Bortezomib metabolite M2
    Bortezomib metabolite M28
• Bortezomib
  Bortezomib metabolite M34
• Bortezomib
  Bortezomib metabolite M23 or M24 (1)
• Bortezomib
  Bortezomib metabolite M23 or M24 (2)

Route of elimination

The pathways of elimination of bortezomib have not been characterized in humans.

Half life

The mean elimination half-life of bortezomib after first dose ranged from 9 to 15 hours at doses ranging from 1.45 to 2.00 mg/m2 in patients with advanced malignancies.

Clearance

• 102 L/h [patients with multiple myeloma following the first dose for doses of 1 mg/m2]
• 112 L/h [patients with multiple myeloma following the first dose for doses of 1.3 mg/m2]
• 15 - 32 L/h [patients with multiple myeloma following subsequent doses for doses of 1 and 1.3 mg/m2]

Toxicity

Cardiovascular safety pharmacology studies in monkeys show that lethal IV doses are associated with decreases in blood pressure, increases in heart rate, increases in contractility, and ultimately terminal hypotension. In monkeys, doses of 3.0 mg/m² and greater (approximately twice the recommended clinical dose) resulted in progressive hypotension starting at 1 hour and progressing to death by 12 to 14 hours following drug administration.

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
(R)-warfarin	The metabolism of (R)-warfarin can be decreased when combined with Bortezomib.
(S)-Warfarin	The metabolism of (S)-Warfarin can be decreased when combined with Bortezomib.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid	The therapeutic efficacy of 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid can be increased when used in combination with Bortezomib.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Bortezomib is combined with 2-Methoxyethanol.
3,5-diiodothyropropionic acid	The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Bortezomib.
4-hydroxycoumarin	The metabolism of 4-hydroxycoumarin can be decreased when combined with Bortezomib.
4-Methoxyamphetamine	The metabolism of 4-Methoxyamphetamine can be decreased when combined with Bortezomib.
5-androstenedione	The metabolism of 5-androstenedione can be decreased when combined with Bortezomib.
6-Deoxyerythronolide B	The metabolism of Bortezomib can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanine	The metabolism of 6-O-benzylguanine can be decreased when combined with Bortezomib.

Food Interactions

• Citrus fruits - Patients should avoid taking extra vitamin C (ascorbic acid) supplements and vitamin C-containing multi-vitamins during their bortezomib therapy. Ascorbic Acid may diminish the therapeutic effect of Bortezomib.
• Green Tea - Green Tea may diminish the antineoplastic effect of Bortezomib. Avoid concurrent use of green tea extract and other green tea products during treatment with bortezomib.

References

Synthesis Reference

Raghavendracharyulu Venkata Palle, Rajasekhar Kadaboina, Veerendeer Murki, Amarendhar Manda, Nageshwar Gunda, Ramaseshagiri Rao Pulla, Mallesha Hanmanthu, Narasimha Naidu Mopidevi, Suresh Kumar Ramdoss, "BORTEZOMIB AND PROCESS FOR PRODUCING SAME." U.S. Patent US20100226597, issued September 09, 2010.

US20100226597

General References

1. Adams J, Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-11. [PubMed:15199612]
2. Bonvini P, Zorzi E, Basso G, Rosolen A: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia. 2007 Apr;21(4):838-42. Epub 2007 Feb 1. [PubMed:17268529]
3. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130]
4. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001]
5. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [PubMed:10363983]
6. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21. [PubMed:15846363]

External Links

Human Metabolome Database

HMDB0014334

KEGG Drug

D03150

PubChem Compound

387447

PubChem Substance

46508736

ChemSpider

343402

BindingDB

50069989

ChEBI

52717

ChEMBL

CHEMBL325041

Therapeutic Targets Database

DAP001318

PharmGKB

PA10252

HET

BO2

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Bortezomib

ATC Codes

L01XX32 — Bortezomib

• L01XX — Other antineoplastic agents
• L01X — OTHER ANTINEOPLASTIC AGENTS
• L01 — ANTINEOPLASTIC AGENTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

AHFS Codes

• 10:00.00 — Antineoplastic Agents

PDB Entries

2f16 / 3mg0 / 4fwd / 4qvl / 4qvm / 4qvn / 4qvp / 4qvq / 4qvv / 4qvw …

show 14 more

FDA label

Download (199 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Active Not Recruiting	Basic Science	Multiple Myeloma (MM)	1
0	Completed	Treatment	Autologous Transplant / Malignant Lymphoma, Stem Cell Type	1
0	Completed	Treatment	Chronic Myeloproliferative Disorders / Leukemias	1
0	Terminated	Treatment	Lymphoma, B-Cell	1
0	Terminated	Treatment	Multiple Myeloma (MM)	1
1	Active Not Recruiting	Basic Science	Soft Tissue Sarcoma Adult	1
1	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
1	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Active Not Recruiting	Treatment	Leukemia Acute Myeloid Leukemia (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
1	Active Not Recruiting	Treatment	Leukemias	1
1	Active Not Recruiting	Treatment	Light Chain Deposition Disease / Primary Systemic Amyloidosis	1
1	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
1	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	3
1	Active Not Recruiting	Treatment	Multiple Myeloma in Relapse	1
1	Active Not Recruiting	Treatment	Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma	1
1	Active Not Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Active Not Recruiting	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma	1
1	Active Not Recruiting	Treatment	Tumors, Solid / Urethral Cancer	1
1	Completed	Basic Science	Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)	1
1	Completed	Other	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
1	Completed	Other	Multiple Myeloma (MM)	1
1	Completed	Prevention	Hematopoetic Stem Cell Transplant	1
1	Completed	Treatment	Acute Lymphocytic Leukemia (ALL) / Chronic Chronic myelogenous leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome	1
1	Completed	Treatment	Acute Myelogenous Leukaemia (AML)	1
1	Completed	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)	1
1	Completed	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Blastic Phase / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Untreated Adult Acute Myeloid Leukemia	1
1	Completed	Treatment	Adult Acute Promyelocytic Leukemia (M3) / Blastic Phase Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia	1
1	Completed	Treatment	Adult Grade III Lymphomatoid Granulomatosis / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Post Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)	1
1	Completed	Treatment	Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Leukemia, Prolymphocytic / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Small Intestine Lymphoma / T-Cell Large Granular Lymphocyte Leukemia	1
1	Completed	Treatment	Advanced Cancer, Various, NOS	1
1	Completed	Treatment	Advanced Malignancy / Malignant Lymphomas / Plasma Cell Myeloma / Tumors, Solid	1
1	Completed	Treatment	Advanced or Metastatic Solid Tumors	1
1	Completed	Treatment	Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Promyelocytic Leukemia (M3) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia	1
1	Completed	Treatment	Brain Cancer / Central Nervous System Neoplasms / Cervix Cancer / Head and Neck Carcinoma	1
1	Completed	Treatment	Brain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Breast Cancer Metastatic	1
1	Completed	Treatment	Cancer of the Ovary / Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma (Skin) / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Cancer of the Ovary / Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers / Sarcomas	1
1	Completed	Treatment	Cancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cancer	1
1	Completed	Treatment	Cancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer	1
1	Completed	Treatment	Cancer, Advanced	2
1	Completed	Treatment	Cancer, Breast / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Carcinoid Tumors / Lung Cancer Small Cell Lung Cancer (SCLC) / Melanoma / Parathyroid Carcinoma / Soft Tissue Sarcoma (STS)	1
1	Completed	Treatment	Childhood Burkitt Lymphoma / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Medulloepithelioma / Childhood Meningioma / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Oligodendroglioma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)	1
1	Completed	Treatment	Chronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Completed	Treatment	Chronic Lymphocytic Leukemia (CLL) - Refractory / Refractory Multiple Myeloma / Stage III Multiple Myeloma / Stage IV Chronic Lymphocytic Leukemia / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Colorectal Cancers	2
1	Completed	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Completed	Treatment	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Plasma Cell Myeloma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Completed	Treatment	Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma	1
1	Completed	Treatment	Glioblastoma Multiforme (GBM)	1
1	Completed	Treatment	Graft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous	1
1	Completed	Treatment	Head and Neck Carcinoma	1
1	Completed	Treatment	Head and Neck Carcinoma / Laryngeal Cancer / Oral Cancers / Pharyngeal Cancer / Squamous Carcinoma	1
1	Completed	Treatment	Hepatic Complications / Neoplasms, Malignant	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma	1
1	Completed	Treatment	Leukemias	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Mature T-cell and Nk-cell Neoplasms / Multiple Myeloma and Plasma Cell Neoplasm	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms	1
1	Completed	Treatment	Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Lymphoma, Hodgkins / Malignant Lymphomas	1
1	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1	Completed	Treatment	Malignancies, Hematologic	1
1	Completed	Treatment	Malignant Lymphomas	2
1	Completed	Treatment	Malignant Lymphomas / Neuroblastomas / Sarcomas / WilmsTumor	1
1	Completed	Treatment	Malignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Completed	Treatment	Malignant Pleural Effusions / Non-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
1	Completed	Treatment	Mantle Cell Lymphoma (MCL)	1
1	Completed	Treatment	Melanoma	2
1	Completed	Treatment	Multiple Myeloma (MM)	18
1	Completed	Treatment	Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
1	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	3
1	Completed	Treatment	Myelodysplasia	1
1	Completed	Treatment	Neuroblastomas	1
1	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
1	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL) / Tumors	1
1	Completed	Treatment	Plasma Cell Myeloma	1
1	Completed	Treatment	Prostate Cancer	1
1	Completed	Treatment	Recurrent Plasma Cell Myeloma	1
1	Completed	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Completed	Treatment	Squamous Cell Carcinoma (SCC)	1
1	Completed	Treatment	Tumors	1
1	Completed	Treatment	Tumors, Solid	2
1	Completed	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	9
1	Completed	Treatment	Unspecified Childhood Solid Tumor, Protocol Specific	1
1	Not Yet Recruiting	Treatment	Acute Myelogenous Leukaemia (AML) / Cancer, Breast / Malignant Neoplasm of Pancreas / Prostate Cancer	1
1	Not Yet Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1	Recruiting	Treatment	Acute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse	1
1	Recruiting	Treatment	Dysferlinopathy	1
1	Recruiting	Treatment	Haematological Malignancies / Plasma Cell Myeloma	1
1	Recruiting	Treatment	Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)	1
1	Recruiting	Treatment	Malignant Lymphomas / Relapsed/Refractory T-cell Lymphomas	1
1	Recruiting	Treatment	Multiple Myeloma (MM)	1
1	Suspended	Treatment	Relapsed/Refractory Multiple Myeloma	1
1	Terminated	Treatment	714leukemia / Malignant Lymphomas	1
1	Terminated	Treatment	Adult Grade III Lymphomatoid Granulomatosis / AIDS-related Peripheral/Systemic Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
1	Terminated	Treatment	Adult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
1	Terminated	Treatment	Adult Non-Hodgkin's Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma	1
1	Terminated	Treatment	Advanced Solid Tumors	1
1	Terminated	Treatment	Lung Cancers	1
1	Terminated	Treatment	Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)	1
1	Terminated	Treatment	Lymphoproliferative Disorders / Malignant Lymphomas	1
1	Terminated	Treatment	Multiple Myeloma (MM)	4
1	Terminated	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1	Terminated	Treatment	Myelodysplastic Syndrome	1
1	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1	Terminated	Treatment	Unspecified Adult Solid Tumor, Protocol Specific	1
1	Unknown Status	Treatment	Multiple Myeloma (MM)	1
1	Unknown Status	Treatment	Refractory Autoimmune Cytopenia(s)	1
1	Withdrawn	Treatment	Leukemia, Plasma Cell	1
1	Withdrawn	Treatment	Multiple Myeloma (MM)	1
1	Withdrawn	Treatment	Multiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma	1
1	Withdrawn	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	1
1, 2	Active Not Recruiting	Prevention	Haematological Malignancies	1
1, 2	Active Not Recruiting	Treatment	Advanced Malignancies / Cancer, Advanced / Metastatic Cancers / Tumors, Solid	1
1, 2	Active Not Recruiting	Treatment	Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Therapy-Related Toxicity / Tiredness / Waldenström's Macroglobulinemia (WM)	1
1, 2	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma	1
1, 2	Active Not Recruiting	Treatment	Kidney Transplant Rejection	1
1, 2	Active Not Recruiting	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
1, 2	Active Not Recruiting	Treatment	Malignant Lymphomas	1
1, 2	Active Not Recruiting	Treatment	Malignant Lymphomas / Mantle Cell Lymphoma (MCL)	1
1, 2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	4
1, 2	Active Not Recruiting	Treatment	Renal Cell Adenocarcinoma	1
1, 2	Active Not Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	1
1, 2	Completed	Prevention	Malignancies, Hematologic	1
1, 2	Completed	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Completed	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia	1
1, 2	Completed	Treatment	Adult T-cell lymphomas/leukaemias	1
1, 2	Completed	Treatment	Amyloidosis	1
1, 2	Completed	Treatment	Cancer of the Ovary / Cancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific	1
1, 2	Completed	Treatment	Follicular Lymphoma (FL) / Lymphoma, B-Cell	1
1, 2	Completed	Treatment	Leukemia Acute Myeloid Leukemia (AML)	2
1, 2	Completed	Treatment	Leukemias / Malignant Lymphomas	1
1, 2	Completed	Treatment	Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific	1
1, 2	Completed	Treatment	Lymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse	1
1, 2	Completed	Treatment	Malignancies, Hematologic / Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	2
1, 2	Completed	Treatment	Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)	1
1, 2	Completed	Treatment	Multiple Myeloma (MM)	10
1, 2	Completed	Treatment	Multiple Myeloma (MM) / Multiple Myeloma in Relapse	1
1, 2	Completed	Treatment	Multiple Myeloma (MM) / Patient Participation	1
1, 2	Completed	Treatment	Multiple Myeloma (MM) / Refractory / Relapses	1
1, 2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	2
1, 2	Completed	Treatment	Multiple Myeloma in Relapse	1
1, 2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	2
1, 2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)	1
1, 2	Completed	Treatment	Non-Small Cell Lung Cancer Recurrent / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer	1
1, 2	Completed	Treatment	Plasma Cell Myeloma	2
1, 2	Completed	Treatment	Prostatic Neoplasms	1
1, 2	Completed	Treatment	Acute, relapsed Leukemia / Refractory Acute Leukemia	1
1, 2	Completed	Treatment	Refractory Multiple Myeloma	2
1, 2	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
1, 2	Not Yet Recruiting	Treatment	Cancer of Colon / Cancer of Liver / Cancer of Pancreas / Cancer of Rectum / Cancer, Gall Bladder / Glioblastoma Multiforme (GBM) / Myeloma Multiple	1
1, 2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
1, 2	Recruiting	Treatment	Glioblastomas	1
1, 2	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
1, 2	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
1, 2	Recruiting	Treatment	Multiple Myeloma (MM)	3
1, 2	Recruiting	Treatment	Recurrent Neuroblastoma	1
1, 2	Recruiting	Treatment	Transplants and Implants	1
1, 2	Recruiting	Treatment	Treatments	1
1, 2	Suspended	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
1, 2	Terminated	Treatment	Brain and Central Nervous System Tumors / Melanoma / Tumors, Solid	1
1, 2	Terminated	Treatment	Colorectal Cancers	1
1, 2	Terminated	Treatment	Malignancies / Multiple Myeloma (MM)	1
1, 2	Terminated	Treatment	Malignant Lymphomas	2
1, 2	Terminated	Treatment	Medullary Thyroid Cancer (MTC)	1
1, 2	Terminated	Treatment	Multiple Myeloma (MM)	4
1, 2	Terminated	Treatment	Plasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma	1
1, 2	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	2
1, 2	Terminated	Treatment	Refractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
1, 2	Unknown Status	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
1, 2	Unknown Status	Treatment	Multiple Myeloma (MM)	2
1, 2	Unknown Status	Treatment	Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation	1
1, 2	Unknown Status	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	2
1, 2	Unknown Status	Treatment	Myelodysplastic Syndromes	1
1, 2	Unknown Status	Treatment	Transplantation, Renal / Uremia	1
1, 2	Withdrawn	Treatment	Lung Cancers	2
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM)	1
1, 2	Withdrawn	Treatment	Multiple Myeloma (MM) / Refractory Multiple Myeloma	1
2	Active Not Recruiting	Supportive Care	Multiple Myeloma (MM)	1
2	Active Not Recruiting	Treatment	Acute Myelogenous Leukaemia (AML)	1
2	Active Not Recruiting	Treatment	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia	1
2	Active Not Recruiting	Treatment	Adult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma	1
2	Active Not Recruiting	Treatment	Amyloidosis	1
2	Active Not Recruiting	Treatment	Ann Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma	1
2	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors	1
2	Active Not Recruiting	Treatment	Chronic Graft Versus Host Disease	1
2	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Active Not Recruiting	Treatment	Contiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma	1
2	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma	2
2	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Estrogen Receptor Positive / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer	1
2	Active Not Recruiting	Treatment	Extramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
2	Active Not Recruiting	Treatment	High-Risk Cancer / Multiple Myeloma (MM)	1
2	Active Not Recruiting	Treatment	Light Chain Deposition Disease / Primary Systemic Amyloidosis	1
2	Active Not Recruiting	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Active Not Recruiting	Treatment	Malignant Lymphomas	1
2	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	2
2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	19
2	Active Not Recruiting	Treatment	Multiple Myeloma and Plasma Cell Neoplasm / Neurologic toxicity	1
2	Active Not Recruiting	Treatment	Obliterative Bronchiolitis	1
2	Active Not Recruiting	Treatment	Refractory Plasma Cell Myeloma	1
2	Active Not Recruiting	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Active Not Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	2
2	Completed	Prevention	Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Leukemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)	1
2	Completed	Prevention	Multiple Myeloma (MM)	1
2	Completed	Treatment	Acinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer	1
2	Completed	Treatment	Adenocarcinoma of the Extrahepatic Bile Duct / Adenocarcinoma of the Gallbladder / Advanced Adult Primary Liver Cancer / Gastrointestinal Cancers / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer	1
2	Completed	Treatment	Adenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Malignant Pleural Effusions / Non-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Adenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Adenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer	1
2	Completed	Treatment	Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)	1
2	Completed	Treatment	Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor	1
2	Completed	Treatment	Adult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma	1
2	Completed	Treatment	Adult Lymphocyte Depletion Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma	1
2	Completed	Treatment	Adult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer	2
2	Completed	Treatment	Advanced Solid Tumors	1
2	Completed	Treatment	Allogeneic Stem Cell Transplantation / Refractory Autoimmune Cytopenia(s)	1
2	Completed	Treatment	Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / Angioimmunoblastic T-Cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Extranodal NK/T-cell Lymphoma Nasal Type / Hepatosplenic T-Cell Lymphoma / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant	1
2	Completed	Treatment	Antibody-mediated Rejection / Late Rejection of Renal Transplant	1
2	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Adult Acute Lymphoblastic Leukemia (ALL) / Ph Positive Adult Acute Lymphoblastic Leukemia / Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia (ALL) / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia (ALL)	1
2	Completed	Treatment	B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia	1
2	Completed	Treatment	Bladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter	1
2	Completed	Treatment	Brain and Central Nervous System Tumors	1
2	Completed	Treatment	CD20 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Lymphocytic Neoplasm / Malignant Lymphomas	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Carcinoid tumour of the gastrointestinal tract / Islet Cell Tumor	1
2	Completed	Treatment	Carcinoma, Adenoid Cystic	1
2	Completed	Treatment	Chronic Graft Versus Host Disease	1
2	Completed	Treatment	Ciliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IV Melanoma	1
2	Completed	Treatment	Colorectal Cancers	1
2	Completed	Treatment	Contiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma	1
2	Completed	Treatment	Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer	1
2	Completed	Treatment	Epstein Barr Virus Infections / Post-transplant Lymphoproliferative Disease (PTLD) / Solid Organ Transplant / Stem Cell Transplant (Bone Marrow Transplant)	1
2	Completed	Treatment	Esophageal Cancers	1
2	Completed	Treatment	Follicular Lymphoma (FL)	2
2	Completed	Treatment	Follicular Lymphoma (FL) / Lymphoma, B-Cell / Marginal Lymphoma	1
2	Completed	Treatment	Glioblastomas / Gliosarcoma	1
2	Completed	Treatment	Gliomas	1
2	Completed	Treatment	Graft Versus Host Disease (GVHD)	1
2	Completed	Treatment	Head and Neck Carcinoma	1
2	Completed	Treatment	Hodgkins Disease (HD)	1
2	Completed	Treatment	Indolent Lymphoma / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / SLL	1
2	Completed	Treatment	Insular Thyroid Cancer / Recurrent Thyroid Cancer / Stage II Follicular Thyroid Cancer / Stage II Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer	1
2	Completed	Treatment	Leukemia, Plasma Cell / Multiple Myeloma (MM)	1
2	Completed	Treatment	Leukemias	2
2	Completed	Treatment	Leukemias / Malignant Lymphomas / Myelodysplastic Syndrome	1
2	Completed	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Completed	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic	1
2	Completed	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Cancer Recurrent / Stage IV Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Lung Cancers	2
2	Completed	Treatment	Lymphoma, B-Cell	2
2	Completed	Treatment	Lymphoma, Hodgkins / Recurrent Classic Hodgkin Lymphoma / Refractory Classic Hodgkin Lymphoma	1
2	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	2
2	Completed	Treatment	Lymphoma, Mucosa-Associated Lymphoid Tissue	1
2	Completed	Treatment	Lymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Completed	Treatment	MALT Lymphoma	1
2	Completed	Treatment	Malignant Lymphomas	13
2	Completed	Treatment	Malignant Lymphomas / Mantle Cell Lymphoma (MCL)	1
2	Completed	Treatment	Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Malignant Neoplasm of Stomach	1
2	Completed	Treatment	Mantle Cell Lymphoma (MCL)	2
2	Completed	Treatment	Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)	1
2	Completed	Treatment	Mesothelioma, Malignant	2
2	Completed	Treatment	Metastatic Bladder Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Stage III Bladder Cancer / Stage III Urethral Cancer / Stage IV Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer	1
2	Completed	Treatment	Multiple Myeloma (MM)	48
2	Completed	Treatment	Multiple Myeloma (MM) / Renal Insuficiency	1
2	Completed	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	6
2	Completed	Treatment	Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma	1
2	Completed	Treatment	Myelodysplastic Syndromes	1
2	Completed	Treatment	Neuromyelitis Optica Spectrum Disorder	1
2	Completed	Treatment	Non Hodgkin's Follicular Lymphoma	1
2	Completed	Treatment	Non Small Cell Lung Carcinoma (NSCLC)	1
2	Completed	Treatment	Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)	1
2	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	4
2	Completed	Treatment	Non-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Completed	Treatment	Peripheral T-Cell Lymphoma (PTCL)	1
2	Completed	Treatment	Plasma Cell Myeloma	1
2	Completed	Treatment	Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer	1
2	Completed	Treatment	Primary Systemic Amyloidosis	1
2	Completed	Treatment	Prostate Cancer	3
2	Completed	Treatment	Prostate Neoplasms	1
2	Completed	Treatment	Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Salivary Gland Adenoid Cystic Carcinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer	1
2	Completed	Treatment	Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma	1
2	Completed	Treatment	Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
2	Completed	Treatment	Recurrent Breast Cancer / Stage IV Breast Cancer	1
2	Completed	Treatment	Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma	1
2	Completed	Treatment	Recurrent Mantle Cell Lymphoma	1
2	Completed	Treatment	Recurrent Melanoma / Stage IV Melanoma	1
2	Completed	Treatment	Recurrent Nasopharyngeal Cancer / Stage IV Nasopharyngeal Cancer	1
2	Completed	Treatment	Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer	1
2	Completed	Treatment	Refractory Cold Agglutinin Disease	1
2	Completed	Treatment	Rejection, Transplant	1
2	Completed	Treatment	Relapse/Refractory Multiple Myeloma	1
2	Completed	Treatment	Relapsed Follicular Lymphoma	1
2	Completed	Treatment	Relapsed Or Refractory Multiple Myeloma	1
2	Completed	Treatment	Renal Cancers	3
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	2
2	Completed	Treatment	Transplant, Kidney / Transplantation, Kidney	1
2	Completed	Treatment	Waldenström's Macroglobulinemia (WM)	4
2	No Longer Available	Not Available	Multiple Myeloma (MM)	1
2	Not Yet Recruiting	Treatment	High Risk / Newly Diagnosed / Plasma Cell Myeloma	1
2	Not Yet Recruiting	Treatment	Immune Thrombocytopenia	1
2	Not Yet Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM)	1
2	Not Yet Recruiting	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2	Not Yet Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	2
2	Recruiting	Basic Science	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Recruiting	Supportive Care	Multiple Myeloma (MM)	1
2	Recruiting	Treatment	Acquired Hemophilia A	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic	1
2	Recruiting	Treatment	Adult-onset Immunodeficiency	1
2	Recruiting	Treatment	Chronic Antibody-mediated Transplant Rejection	1
2	Recruiting	Treatment	Chronic Kidney Disease (CKD) / Multiple Myeloma (MM)	1
2	Recruiting	Treatment	HHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies	1
2	Recruiting	Treatment	Haematological Malignancies	1
2	Recruiting	Treatment	Interstitial Lung Disease (ILD) / Scleroderma / Sclerosis, Progressive Systemic	1
2	Recruiting	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
2	Recruiting	Treatment	Lymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM)	1
2	Recruiting	Treatment	Malignant Lymphomas / Neurologic toxicity / Therapy-Related Toxicity	1
2	Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	2
2	Recruiting	Treatment	Multiple Myeloma (MM)	9
2	Recruiting	Treatment	Myasthenia Gravis / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE)	1
2	Recruiting	Treatment	Neuroblastomas	1
2	Recruiting	Treatment	Plasma Cell Myeloma	1
2	Recruiting	Treatment	Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma	1
2	Recruiting	Treatment	Refractory Multiple Myeloma	1
2	Recruiting	Treatment	Relapsed Acute Promyelocytic Leukemia	1
2	Recruiting	Treatment	Relapsed and/or Refractory Cutaneous T-cell Lymphoma	1
2	Suspended	Treatment	Cancer - Multiple Myeloma / Multiple Myeloma (MM)	1
2	Terminated	Prevention	Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukemia, Acute / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Small Lymphocytic Lymphoma (SLL)	1
2	Terminated	Prevention	Disorder of Transplanted Kidney	1
2	Terminated	Prevention	Graft Versus Host Disease (GVHD)	1
2	Terminated	Prevention	Malignancies / Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2	Terminated	Prevention	Multiple Myeloma (MM)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic	1
2	Terminated	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia	1
2	Terminated	Treatment	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)	1
2	Terminated	Treatment	Adenocarcinoma, Bronchiolo-Alveolar / Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Terminated	Treatment	Cardiac Transplant / Heart Transplantation / Primary Heart Transplant	1
2	Terminated	Treatment	Cervical Cancers	1
2	Terminated	Treatment	Follicular Lymphoma (FL)	4
2	Terminated	Treatment	Hodgkins Disease (HD)	1
2	Terminated	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell / Mantle Cell Lymphoma (MCL)	1
2	Terminated	Treatment	Leukemias	1
2	Terminated	Treatment	Leukemias / Myelodysplastic Syndrome	1
2	Terminated	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	2
2	Terminated	Treatment	Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)	1
2	Terminated	Treatment	Lymphoma, Mucosa-Associated Lymphoid Tissue	1
2	Terminated	Treatment	Lymphoproliferative Disorders	1
2	Terminated	Treatment	Malignant Lymphomas	3
2	Terminated	Treatment	Malignant Neoplasm of Pancreas	1
2	Terminated	Treatment	Malignant Neoplasm of Stomach	1
2	Terminated	Treatment	Mantle Cell Lymphoma (MCL)	1
2	Terminated	Treatment	Metastatic Breast Cancer (MBC)	1
2	Terminated	Treatment	Metastatic Renal Cell Carcinoma	1
2	Terminated	Treatment	Multiple Myeloma (MM)	17
2	Terminated	Treatment	Non-Hodgkin's Lymphoma (NHL)	3
2	Terminated	Treatment	Non-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer	1
2	Terminated	Treatment	Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma	1
2	Terminated	Treatment	Refractory Multiple Myeloma	1
2	Terminated	Treatment	Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2	Terminated	Treatment	Refractory Plasma Cell Myeloma	1
2	Terminated	Treatment	Smith-Magenis Syndrome	1
2	Terminated	Treatment	Stage IIIB or IV Non-Small Cell Lung Cancer	1
2	Terminated	Treatment	Waldenström's Macroglobulinemia (WM)	1
2	Unknown Status	Treatment	Bortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma	1
2	Unknown Status	Treatment	End Stage Renal Disease (ESRD)	1
2	Unknown Status	Treatment	Leukemia, Plasma Cell / Multiple Myeloma (MM)	1
2	Unknown Status	Treatment	Mantle Cell Lymphoma (MCL)	1
2	Unknown Status	Treatment	Mesothelioma	1
2	Unknown Status	Treatment	Multiple Myeloma (MM)	6
2	Unknown Status	Treatment	Multiple Myeloma and Plasma Cell Neoplasm	3
2	Unknown Status	Treatment	Nasopharyngeal Carcinoma	1
2	Unknown Status	Treatment	Waldenström's Macroglobulinemia (WM)	1
2	Withdrawn	Prevention	Multiple Myeloma (MM)	1
2	Withdrawn	Treatment	Acute Lymphocytic Leukemia (ALL) / Leukemias	1
2	Withdrawn	Treatment	Amyloidosis / Immunoglobulin Light Chain Deposition	1
2	Withdrawn	Treatment	Cancer of the Ovary	1
2	Withdrawn	Treatment	Malignancies	1
2	Withdrawn	Treatment	Malignant Lymphomas	1
2	Withdrawn	Treatment	Multiple Myeloma (MM)	4
2	Withdrawn	Treatment	Multiple Myeloma (MM) / Multiple Myeloma in Relapse	1
2	Withdrawn	Treatment	Multiple Myeloma (MM) / Plasma Cell Myeloma	1
2	Withdrawn	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
2	Withdrawn	Treatment	Plasma Cell Myeloma	1
2	Withdrawn	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
2, 3	Completed	Treatment	Multiple Myeloma (MM)	2
2, 3	Recruiting	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma	1
2, 3	Terminated	Treatment	Multiple Myeloma (MM)	1
3	Active Not Recruiting	Treatment	DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Active Not Recruiting	Treatment	Mantle Cell Lymphoma (MCL)	1
3	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	9
3	Active Not Recruiting	Treatment	Plasma Cell Myeloma	1
3	Active Not Recruiting	Treatment	Previously Untreated Symptomatic Multiple Myeloma	1
3	Completed	Not Available	Multiple Myeloma (MM)	1
3	Completed	Diagnostic	Multiple Myeloma (MM)	1
3	Completed	Treatment	Amyloidosis	1
3	Completed	Treatment	Effects of Chemotherapy / Multiple Myeloma (MM)	1
3	Completed	Treatment	Granulocytic Sarcoma / Leukaemia cutis / Leukemia Acute Myeloid Leukemia (AML) / Myeloid Neoplasm / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm	1
3	Completed	Treatment	Light Chain Deposition Disease / Primary Systemic Amyloidosis	1
3	Completed	Treatment	Lymphoma, Large B-Cell, Diffuse (DLBCL)	1
3	Completed	Treatment	Multiple Myeloma (MM)	27
3	Completed	Treatment	Non-Hodgkin's Lymphoma (NHL)	1
3	No Longer Available	Not Available	Multiple Myeloma (MM)	1
3	Not Yet Recruiting	Treatment	Immune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic	1
3	Recruiting	Treatment	Acute Lymphoblastic Leukemia, Pediatric	1
3	Recruiting	Treatment	Amyloidosis	1
3	Recruiting	Treatment	Auto Stem Cell Transplant / Multiple Myeloma (MM)	1
3	Recruiting	Treatment	Intrahepatic Cholangiocarcinoma	1
3	Recruiting	Treatment	Multiple Myeloma (MM)	9
3	Recruiting	Treatment	Newly Diagnosed Multiple Myeloma	1
3	Recruiting	Treatment	Plasma Cell Myeloma	1
3	Recruiting	Treatment	Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	1
3	Suspended	Treatment	Acute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult Lymphoblastic Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia	1
3	Suspended	Treatment	Relapsed/Refractory Multiple Myeloma	1
3	Terminated	Treatment	AL Amyloidosis	1
3	Terminated	Treatment	Multiple Myeloma (MM)	5
3	Terminated	Treatment	Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma	1
3	Unknown Status	Treatment	Multiple Myeloma (MM)	2
3	Unknown Status	Treatment	Transplantation, Kidney	1
3	Withdrawn	Treatment	Malignant Lymphomas	1
3	Withdrawn	Treatment	Multiple Myeloma (MM)	1
4	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
4	Completed	Not Available	Hematological Neoplasms / Multiple Myeloma (MM)	2
4	Completed	Not Available	Multiple Myeloma (MM)	7
4	Completed	Prevention	Transplantation, Kidney	1
4	Completed	Treatment	Chronic Kidney Disease (CKD) / IgA Nephropathy	1
4	Completed	Treatment	HLA Sensitization	1
4	Completed	Treatment	Multiple Myeloma (MM)	3
4	Recruiting	Treatment	Hematological Neoplasms	1
4	Recruiting	Treatment	Multiple Myeloma (MM)	2
4	Recruiting	Treatment	Patients Awaiting a Living Kidney Donation	1
4	Recruiting	Treatment	Pompe's Disease	1
4	Recruiting	Treatment	Relapsed and/or Refractory Multiple Myeloma	1
4	Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	1
4	Withdrawn	Treatment	Hematuria / Nephritis, Lupus / Proteinuria	1
Not Available	Active Not Recruiting	Not Available	Multiple Myeloma (MM)	1
Not Available	Active Not Recruiting	Treatment	Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM)	1
Not Available	Available	Not Available	Multiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma	1
Not Available	Completed	Not Available	Amyloidosis	1
Not Available	Completed	Not Available	Cardiotoxins / Heart Failure, Systolic / Multiple Myeloma (MM)	1
Not Available	Completed	Not Available	Multiple Myeloma (MM)	1
Not Available	Completed	Treatment	Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes	1
Not Available	Completed	Treatment	Amyloidosis	1
Not Available	Completed	Treatment	Multiple Myeloma (MM)	1
Not Available	Not Yet Recruiting	Not Available	Chemotherapy Induced Peripheral Neuropathy / Multiple Myeloma (MM)	1
Not Available	Recruiting	Treatment	Amyloidosis; Systemic	1
Not Available	Recruiting	Treatment	Antibody-mediated Rejection	1
Not Available	Recruiting	Treatment	Childhood Acute Lymphoblastic Leukemia	1
Not Available	Terminated	Treatment	Follicular Lymphoma (FL) / Malignant Lymphomas / Marginal Zone Lymphoma	1
Not Available	Terminated	Treatment	Sickle Cell Disorders / Sickle Cell-hemoglobin C Disease / Sickle Cell-β0-thalassemia	1

Pharmacoeconomics

Manufacturers

• Millennium pharmaceuticals inc

Packagers

• Ben Venue Laboratories Inc.
• Janssen-Ortho Inc.
• Millennium Pharmaceuticals

Dosage forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Intravenous	1 mg/1mL
Injection, powder, for solution	Intravenous; Subcutaneous	3.5 mg
Powder, for solution	Intravenous; Subcutaneous	2.5 mg
Injection, powder, for solution	Intravenous	1.0 mg
Injection, powder, lyophilized, for solution	Intravenous; Subcutaneous	3.5 mg/1
Powder, for solution	Intravenous; Subcutaneous	3.5 mg

Prices

Unit description	Cost	Unit
Velcade 3.5 mg vial	1590.0USD	vial

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6083903	No	2000-07-04	2014-10-28
CA2203936	No	2005-04-12	2015-10-27
US5780454	Yes	1998-07-14	2017-11-03
US6958319	Yes	2005-10-25	2022-07-25
US6713446	Yes	2004-03-30	2022-07-25
US8962572	No	2015-02-24	2032-11-03

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	The solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0532 mg/mL	ALOGPS
logP	0.89	ALOGPS
logP	1.53	ChemAxon
logS	-3.9	ALOGPS
pKa (Strongest Acidic)	13.04	ChemAxon
pKa (Strongest Basic)	-0.7	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	124.44 Å2	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	99.37 m3·mol-1	ChemAxon
Polarizability	40.48 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	-	0.6935
Blood Brain Barrier	-	0.6533
Caco-2 permeable	-	0.6576
P-glycoprotein substrate	Substrate	0.5909
P-glycoprotein inhibitor I	Non-inhibitor	0.785
P-glycoprotein inhibitor II	Non-inhibitor	1.0
Renal organic cation transporter	Non-inhibitor	0.9445
CYP450 2C9 substrate	Non-substrate	0.7145
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Non-substrate	0.5209
CYP450 1A2 substrate	Non-inhibitor	0.855
CYP450 2C9 inhibitor	Non-inhibitor	0.8267
CYP450 2D6 inhibitor	Non-inhibitor	0.9304
CYP450 2C19 inhibitor	Non-inhibitor	0.8108
CYP450 3A4 inhibitor	Non-inhibitor	0.7308
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9604
Ames test	Non AMES toxic	0.7439
Carcinogenicity	Non-carcinogens	0.8064
Biodegradation	Not ready biodegradable	0.9943
Rat acute toxicity	2.4537 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9936
hERG inhibition (predictor II)	Non-inhibitor	0.8593

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4i-0035900000-122163b342b985220f63
MS/MS Spectrum - , positive	LC-MS/MS	splash10-016r-1397000000-e168634cfe7e1453d742

Taxonomy

Description

This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Phenylalanine and derivatives

Alternative Parents

N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Amphetamines and derivatives / Pyrazinecarboxamides / 2-heteroaryl carboxamides / Fatty amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Boronic acids / Organic metalloid saltsAzacyclic compounds / Carbonyl compounds / Hydrocarbon derivatives / Monoalkylboranes / Organic oxides / Organonitrogen compounds / Organopnictogen compounds

show 7 more

Substituents

Phenylalanine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Amphetamine or derivatives / Pyrazine carboxylic acid or derivatives / Pyrazinecarboxamide / 2-heteroaryl carboxamide / Monocyclic benzene moiety / Fatty amide / PyrazineBenzenoid / Fatty acyl / Heteroaromatic compound / Boronic acid derivative / Boronic acid / Carboxamide group / Secondary carboxylic acid amide / Azacycle / Organic metalloid salt / Organoheterocyclic compound / Hydrocarbon derivative / Organic oxide / Organooxygen compound / Organonitrogen compound / Organoboron compound / Organopnictogen compound / Alkylborane / Carbonyl group / Organic oxygen compound / Organic nitrogen compound / Monoalkylborane / Organic salt / Aromatic heteromonocyclic compound

show 23 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

pyrazines, amino acid amide, L-phenylalanine derivative (CHEBI:52717)

Drug created on June 13, 2005 07:24 / Updated on April 16, 2019 22:04